Found 15 matching trials
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies PHASE1 The purpose of this study is to characterize the pharmacokinetics (PK) of a...
Show More Location
Magyar Honvedseg Egeszsegugyi Kozpont
Learn More & Join Trial
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation PHASE2 This open-label, multi-center study will evaluate the safety and efficacy o...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) PHASE3 This randomized, open-label study evaluated the efficacy, safety and tolera...
Show More Location
Multiple Locations
Learn More & Join Trial
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer PHASE1 The goal of this clinical research study is to find the highest tolerable d...
Show More Location
University of Texas MD Anderson Cancer Center
Learn More & Join Trial
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) PHASE2 This trial will evaluate the efficacy and safety of various therapies in pa...
Show More Location
City of Hope Comprehensive Cancer Center
Learn More & Join Trial
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants PHASE1 This open-label, Phase I study will evaluate the impact of severe hepatic i...
Show More Location
California Cancer Associates for Research & Excellence, Inc.
Learn More & Join Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas PHASE1 The purpose of this first-in-human study of CX-072 is to characterize the s...
Show More Location
PROCLAIM Investigative Site
Learn More & Join Trial
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma PHASE1 The main purpose of this study is to determine the maximum tolerated dose (...
Show More Status
Active Not Recruiting
Location
H. Lee Moffitt Cancer Center and Research Institute
Learn More & Join Trial
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases PHASE2 This is a phase II, open label, non-randomised study of vemurafenib and cob...
Show More Location
Technische Universität Dresden
Learn More & Join Trial
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) N/A This is a multicentre, ambispective (both retrospective and prospective), a...
Show More Location
Centre Hospitalier d'Albi
Learn More & Join Trial